MONTGOMERY COUNTY, Pa. (CBS) — On Tuesday, Plymouth Meeting-based company Inovio Pharmaceuticals announced positive results from early-stage testing of its COVID-19 vaccine. But officials with the biotechnology company did not disclose complete data.
This sent shares of the company’s stock tumbling on Wall Street.READ MORE: Stimulus Check Update: When Might Your $1,400 Economic Relief Payment Arrive?
Inovio’s CEO explains the vaccine testing results.READ MORE: WATCH LIVE: Philadelphia Officials To Give Comments Related To Inspector General's Report Regarding City's Relationship With Philly Fighting COVID, Inc.
Six weeks ago, 36 people received two injections of the COVID-19 vaccine.
“Early phase 1 clinical trials on the COVID-19 vaccine that Inovio is developing demonstrated a very strong safety and very early but very promising immune responses from the trial,” Dr. J. Joseph Kim said.
Inovio says 94% of the trial participants demonstrated overall immune responses.MORE NEWS: Philadelphia Courthouse Evacuated After Police Receive Report Device Was Left At Building
The company says it hopes to get data supporting the effectiveness of its COVID-19 vaccine early next year.